WuXi Biologics (Cayman) Inc. (HKG:2269)
45.58
-3.82 (-7.73%)
Oct 22, 2026, 2:05 PM HKT
WuXi Biologics Employees
WuXi Biologics had 14,705 employees as of June 30, 2026. The number of employees increased by 1,453 or 10.96% since the number was reported on December 31, 2025. That makes WuXi Biologics the 2,443rd largest employer in the world and 210th in Hong Kong.
Employees
14,705
Change
1,453
Growth
10.96%
Revenue / Employee
1.85M HKD
Profits / Employee
393.24K HKD
Market Cap
187.05B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 14,705 | 1,453 | 10.96% |
| Dec 31, 2025 | 13,252 | 677 | 5.38% |
| Dec 31, 2024 | 12,575 | -165 | -1.30% |
| Dec 31, 2023 | 12,740 | 367 | 2.97% |
| Dec 31, 2022 | 12,373 | 2,509 | 25.44% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| BeOne Medicines AG | 12,000 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
WuXi Biologics News
- 23 hours ago - WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026 - PRNewsWire
- 7 days ago - WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence - PRNewsWire
- 11 days ago - WuXi Biologics (SEHK:2269) -- Strong Earnings and Market Expansion | Baird Funds Q3 2026 - GuruFocus
- 27 days ago - WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability - PRNewsWire
- 5 weeks ago - WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership - PRNewsWire
- 5 weeks ago - Big Pharma Is Pouring Billions Into China's Biotechs - Barrons
- 6 weeks ago - Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies - PRNewsWire
- 7 weeks ago - WuXi Biologics price target raised to HK$62 from HK$51.10 at UBS - TheFly